A Phase 3 trial tests a weekly subcutaneous auto-injector for men with low testosterone while a urology panel debates whether lifestyle changes should precede or accompany hormone therapy.
The trial, registered as NCT07898072, enrolls adult males aged 18 to 75 with hypogonadism. Treatment starts at 75 mg weekly, with dose adjustments to 50 mg or 100 mg based on serum testosterone levels measured during the study.
Participants self-administer the auto-injector into the abdomen after an initial dose given by study personnel, continuing through a 24-week primary evaluation period with optional safety follow-up to week 52.
The study uses a prefilled, single-blind, single-arm design across multiple centers. All participants receive testosterone cypionate subcutaneously once weekly via the auto-injector. Pharmacokinetic sampling at weeks 1 and 12 captures full 168-hour profiles to calculate area under the curve and maximum concentrations.
Safety monitoring includes adverse events, clinical laboratory parameters, vital signs, physical examinations, and assessments standard for testosterone replacement therapy. The trial also measures participant experience with the device, including ease of use and successful self-administration, through questionnaires and study diaries.
Men with clinically significant cardiovascular, kidney, liver, blood, psychiatric, neurological, endocrine, gastrointestinal, or respiratory disorders that could interfere with participation or increase risk are excluded. Endocrine conditions other than hypogonadism are permitted only if replacement medication has been stable for at least three months before enrollment.
Severe kidney impairment — defined as an estimated glomerular filtration rate below 30 mL/min — and liver enzyme levels (ALT or AST) more than three times the upper limit of normal also disqualify candidates. Positive screening tests for HIV, hepatitis B surface antigen, or hepatitis C antibody are exclusionary.
A Urology Times webinar published November 20, 2026, convened a panel to discuss testosterone therapy targets, formulations, and future directions. The discussion framed formulation selection around cost, compliance, convenience, and concentration. Panelists said newer oral options may help men who abandon injections, and that the first formulation chosen is simply a starting point, revisited as preferences, insurance coverage, and clinical response evolve.
Emerging evidence suggests oral formulations may spare spermatogenesis, and modern oral products avoid the liver toxicity concerns of older agents.
The panel revealed a notable split on weight loss as a prerequisite for treatment. Dr. Helen L. Bernie, DO, MPH, rejected telling men to lose weight before starting testosterone, arguing that lifestyle change and therapy work best together. Dr. Khera cited trial evidence supporting that combined approach.
Dr. Amy M. Pearlman, MD, emphasized that exogenous testosterone suppresses sperm production and that alternatives such as clomiphene or enclomiphene — oral agents that stimulate the body’s own testosterone production — should be tried first, not only for men concerned about fertility.
The panel closed with a call for approved testosterone therapy for women. As of 2026, no FDA-approved testosterone product exists for women in the United States; female-dose products such as AndroFeme are available only in other countries like Australia.
U.S. prescribing relies on compounded transdermal creams at female physiologic doses (typically 1–5 mg/day) or fractional doses of male-indicated products, all off-label. The panelists stressed that the goal is female physiologic, not supraphysiologic, dosing, with monitoring of total and free testosterone, SHBG, estradiol, CBC, lipids, and liver enzymes at baseline, 6–8 weeks, and every six months thereafter.
The trial is sponsored by Avant Sante Research Center S.A. de C.V., with study identifier AS/CT/CN/ENE-26/002. Records and results are reviewed by the National Library of Medicine before posting on ClinicalTrials.gov.